News coverage about Edge Therapeutics (NASDAQ:EDGE) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edge Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.086270040552 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce ($0.47) Earnings Per Share (americanbankingnews.com)
- Critical Review: Edge Therapeutics (EDGE) vs. Its Competitors (americanbankingnews.com)
- Analyzing Edge Therapeutics (EDGE) & Its Peers (americanbankingnews.com)
- Analyzing Edge Therapeutics (EDGE) and Its Rivals (americanbankingnews.com)
- Edge Therapeutics (EDGE) vs. Its Competitors Critical Analysis (americanbankingnews.com)
A number of research firms recently commented on EDGE. BidaskClub downgraded Edge Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Zacks Investment Research raised Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Monday, November 6th.
Edge Therapeutics (NASDAQ:EDGE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.11. equities analysts predict that Edge Therapeutics will post -1.7 earnings per share for the current fiscal year.
In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.86, for a total transaction of $73,950.00. Following the completion of the transaction, the insider now owns 95,236 shares of the company’s stock, valued at $939,026.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Albert N. Marchio II sold 3,361 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $10.00, for a total value of $33,610.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,861 shares of company stock valued at $378,035. Insiders own 36.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/19/edge-therapeutics-edge-receiving-somewhat-positive-press-coverage-study-finds.html.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.